Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » ETNB.OB

 - UBBFriend: Email this page to someone!    
Author Topic: ETNB.OB
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB news Entest BioMedical, Inc. Chairman & CEO Addressed Shareholders on Its New Company Blog Site Regarding COPD and Immunotherapeutic
Date : 03/11/2010 @ 8:00AM
Source : MarketWire
Stock : Entest BioMedical, Inc (ENTB)
Quote : 1.39 0.0 (0.00%) @ 8:09AM


Entest BioMedical, Inc. Chairman & CEO Addressed Shareholders on Its New Company Blog Site Regarding COPD and Immunotherapeutic

SAN DIEGO, CA -- (Marketwire)
03/11/10
Entest BioMedical, Inc. (OTCBB: ENTB) announced today its CEO David Koos addressed the Company's shareholders and other interested parties on its new blog site. Topics covered in the interview included progress in the Stem Cell / Photoceutical treatment for COPD, immunotherapeutic cancer vaccine, potential grant funding and anticipated revenue sources for the Company. This interview may be heard on the Company's blog site, www.entestbioblog.com/live.

Entest Chairman & CEO David Koos stated, "The Company intends to hold live interviews on its blog site to clarify and update shareholders on progress being made by the Company. Also, there will be an opportunity for open forum discussions on news items previously announced. It is the Company's intention to utilize this blog site to address future plans as they develop."

Future webcasts will be announced prior to taking place so those wishing to participate can logon and join the discussion. Should you miss any interviews, they will be recorded and available on demand later.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576™ is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical, Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-8-16.pdf

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Follow the Company's progress on Twitter:

http://twitter.com/Entest_BioMed

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
Highlights / Synopsis from the ENTB CEO update March/11/10

- they are very excited about bringing Dr. Bogin on the team

- Dr. Bogin will put them in a position to identify key protocols

- will help speed up FDA approval

- the identification of new stem cell line gives them a dramatic and envious platform from which to move forward from

- other scientists working with stem cells may find their platform advantageous or useful to their own line of study which will create added revenue from research companies and pharmaceuticals

- very excited about their cancer immunotherapy vaccine which they are initially rolling out to the vetrinary market. Represents a significant near term revenue stream

- COPD is the fourth leading cause of death in the United States

- no one has come up with a cure to cause lung capacity to regenerate and this is what they are focused on doing

- they feel very confident about FDA approval. Their vaccine which activates stem cells in the body couple with the laser technology which paints the tissue and attracts stem cells to it should get them to the market place faster than other directions they could have gone in

Shareholders were then allowed to ask questions. This will be the first of a townhall like broadcast.


Key Points:

Share structure: Only 2.7 million shares available in the public float. They are not interested in flooding the market with stock and want to keep the tight share structure. Their goal is to focus on research and execution

Moving to a Higher Exchange: The higher up they go in price the more visibility and credibility they get and they are interested in applying to a higher exchange

They are fully reporting on the OTC and not interested in doing any kind of forward split or reverse split. They love their share structure just the way that it is

They are being watched right now by larger stem cell companies but the highest priority now is setting up the protocols

Dr. Bogin is currently analyzing current clinical trials to determine the best direction to proceed in. His clinical background helps with their roadmand and everyone is excited about the journey. His involvement is having an immediate impact

They are not concerned about their cash burn rate because they expect revenue in the next 9 - 12 months from their canine cancer immunotherapy. This will also provide great clinical data for later human trials.

They are estimating grossing $6.2 million dollars from their first year of canine cancer immunotherapy

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
CEO blog link

http://www.entestbioblog.com/live.

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB 1.40
Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB News SAN DIEGO, CA--(Marketwire - 03/15/10) - Entest BioMedical Inc. (OTC.BB:ENTB - News) announced today It is creating a bioinformatics-based program combining advances in molecular knowledge of Chronic Obstructive Pulmonary Disease (COPD) with computer-powered search tools to integrate existing and newly generated data for this condition. Bioinformatics is defined as the collection, classification, storage, and analysis of biochemical and biological information using computers especially as applied in molecular genetics and genomics. One of the best known applications of bioinformatics methods is the Human Genome Project.

"While there are many pieces to the puzzle of COPD, the majority of research today is focused on finding new pieces as opposed to making sense of the pieces we already have," said Dr. Feng Lin, Scientific Director of Entest. "We have begun a Program based on using various automated algorithms to mine existing data sets and develop hypotheses that can be experimentally tested."

One of the initial tasks of the program is the creation of databases containing all genes associated with various aspects of COPD. These genes will then categorized based on biological functionality and association with each other. Once a global perspective of the genes and how their functions inter-relate is achieved, examination can be made as to which existing drugs may act somewhere on the pathway and possibility induce a benefit.

"By assembling everything known in the literature regarding COPD at a molecular level, our scientists will have an overall understanding of this terrible disease," said David Koos. "In addition, the bioinformatics approach will allow Entest to develop new intellectual property, some of which we anticipate will include new uses of existing drugs on the market."

The basis for the current program originates from internal Entest discussions involving the need for appropriate biomarkers for planned photoceutical trials. Given that the mechanism of action of photoceuticals is still relatively unclear, clinical trials will require sensitive biomarkers, which to some extent are not available in COPD. It is anticipated that the bioinformatics program will be of benefit in this aspect.

The Company will be hosting another interview with Its Chairman & CEO on Wednesday morning at 11 a.m. PDT at Live! | Entest BioMedical Blog - ENTB. Mr. Koos will discuss the importance of this new bioinformatics approach on strengthening Its COPD treatment model.

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB the otctimes has picked it up

check it out

http://www.otctimes.com/

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Lockman
Member


Member Rated:
4
Icon 1 posted      Profile for Lockman     Send New Private Message       Edit/Delete Post   Reply With Quote 
http://stockcharts.com/h-sc/ui?s=ENTB&p=D&b=5&g=0&id=p42174716091

--------------------
Let's Go METS!!!

Posts: 3316 | From: CT | Registered: Dec 2006  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB The Company will be hosting another
interview with Its Chairman & CEO on Wednesday
morning at 11 a.m. PDT at
www.Entestbioblog.com/live. Mr. Koos will
discuss the importance of this new bioinformatics
approach on strengthening

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB CEO interview http://www.Entestbioblog.com/live. at 2:00 pm EST
Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB Check out this monster Chart!!!!
http://stockcharts.com/c-sc/sc?s=entb&p=D&b=5&g=0&i=p63557868339&r=4906

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB Entest BioMedical Files Patent Application on Chemokine Technology to Increase Efficacy of Tissue-Specific Stem Cell Homing in COPD Treatment SAN DIEGO, CA--(Marketwire - 03/23/10) - Entest BioMedical Inc. (OTC.BB:ENTB - News) announced today the filing of a patent application covering the use of stem cell attracting molecules called chemokines in the treatment of Chronic Obstructive Pulmonary Disease (COPD) as well as other conditions that may benefit from enhanced stem cell homing.

Chemokines are naturally produced by the body in times of tissue injury and are believed to be an essential part of the healing process. Entest's intellectual property utilizes these molecules to attract stem cells to damaged tissue in order to augment efficacy of both existing and newly developed cell therapies.

"Clinical trials of stem cells have demonstrated safety and signs of efficacy in heart failure, liver failure, and peripheral artery disease. Unfortunately there is still much room for improvement in patient outcomes," stated Dr. Steven Josephs, lead inventor of the patent application. "The current invention offers a means of making stem cell therapy work better by increasing the number of stem cells in the tissue where they are needed."

The FDA has previously approved a drug which functions by alteration of stem cell homing. Mozobil, a drug developed by Genzyme Corporation, is used to induce stem cells to leave a specific anatomical location (bone marrow). The methods covered by the Entest patent application function in an opposite manner by utilizing specific molecules to attract stem cells.

"Today's patent filing represents Entest's global strategy of addressing COPD through a multi-disciplinary manner," said David Koos, Chairman and CEO of Entest. "Since some of these technologies may be useful in augmentation of stem cell therapy for other indications, we are always looking for partnerships for development in our non-core areas."

Entest's Chairman & CEO David Koos, along with lead inventor Dr. Steven Josephs will host a webcast discussion of this new technology on March 24, 2010 at 11:00 am PST. Interested parties can logon to the webcast at www.entestbioblog.com/live.

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
Entest BioMedical CEO ;&; Lead Inventor Clarify Significance of Chemokine Technology in Potential Efficacy of COPD Stem Cell / Photoceutical Therapy
Entest BioMedical CEO ;&; Lead Inventor Clarify Significance of Chemokine Technology in Potential Efficacy of COPD Stem Cell / Photoceutical Therapy
Chemokines Believed to Aid in Stem Cell Homing in Tissue Damaged by COPD
SAN DIEGO, CA, Mar. 25, 2010 (Marketwire) --

SAN DIEGO, CA -- (Marketwire) -- 03/25/10 -- Entest BioMedical Inc. (OTCBB: ENTB) announced today that Chairman & CEO David Koos, along with Lead Inventor Dr. Steven Josephs, provided clarification on the Company's new patent application for use of chemokines in its stem cell / photoceutical therapy for treatment of Chronic Obstructive Pulmonary Disease (COPD) during the Company's weekly blogcast held March 23, 2010.

Dr. Josephs noted, "Chemokines are naturally produced in the body during times of injury and are believed to be an essential part of the healing process. These chemokines cause stem cells to 'home' to injured areas. It is our belief the addition of chemokines to our COPD treatment model will aid in focusing stem cells towards damaged lung tissue painted by our photoceutical device."

Entest's Chairman & CEO David Koos said, "In its simplest form, our COPD treatment model consists of three components: an alarm clock, a bus for transportation and a GPS navigational system. An FDA approved stem cell mobilizer acts as an alarm clock activating the stem cells. Chemokines serve as the 'bus' transporting the stem cells to a location in the body. The laser serves as a GPS system navigating the bus to the destination -- damaged lung tissue."

The entire blogcast has been archived on the Company's blog site: www.entestbioblog.com.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576™ is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest BioMedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf.

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB Entest BioMedical CEO to Interview Noted Stem Cell Transplant Physician Dr. Ewa Carrier on Advances in Stem Cell Therapy
SAN DIEGO, CA -- (Marketwire)
03/26/10
Entest BioMedical Inc. (OTCBB: ENTB) announced today that Chairman & CEO David Koos will interview noted stem cell transplant physician Dr. Ewa Carrier on the Company's weekly blogcast Wednesday, March 31, 2010 at 11:00 a.m. PST. Dr. Carrier is an internationally recognized expert in stem cell transplantation and a member of Entest's Scientific Advisory Board.
Topics to be covered in the interview will include the role of stem cells in treating cancer, advances in heart and lung treatment with stem cell therapy and the use of stem cells in creating blood for transfusion from stem cells.

Entest's Chairman & CEO David Koos stated, "We are extremely fortunate to have Dr. Carrier on our Scientific Advisory Board. Her knowledge in stem cell therapy applications is of great significance to Entest as the Company moves forward."

The blogcast can be accessed at Company's blog site: www.entestbioblog.com/live Wednesday March 31, 2010 at 11:00 am PST.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576? is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest Biomedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
Jacob14
Member


Member Rated:
4
Icon 1 posted      Profile for Jacob14     Send New Private Message       Edit/Delete Post   Reply With Quote 
ENTB 2.11 The blogcast can be accessed at
Company's blog site:
www.entestbioblog.com/live Wednesday
March 31, 2010 at 2:00 pm EST.

Posts: 394 | Registered: Sep 2008  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share